AA
KRON

ALPS Advisors’s Kronos Bio KRON Stock Holding History

ALPS Advisors’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-31,034
Closed -$104K – 1063
2022
Q3 		$104K Sell
31,034
-2,617
-8% -$11.8K ﹤0.01% 1030
2022
Q2 		$122K Sell
33,651
-24,525
-42% -$111K ﹤0.01% 1021
2022
Q1 		$421K Sell
58,176
-7,036
-11% -$60K ﹤0.01% 460
2021
Q4 		$886K Buy
+65,212
New +$1.02M 0.01% 377

Other funds holding KRON

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

ALPS Advisors's KRON Position: Q4 2022 in Review

ALPS Advisors sold out of Kronos Bio (KRON) in Q4 2022, closing a stake of 31,034 shares — an estimated $104K sold.

ALPS Advisors first reported a position in KRON in Q4 2021 and held it in 4 quarters. The position peaked at $886K in Q4 2021. 97 funds tracked by Wall St. Rank hold KRON as of Q4 2022.

  • ALPS Advisors reported no remaining Kronos Bio position as of Q4 2022 after selling out during the quarter.
  • ALPS Advisors sold 31,034 Kronos Bio shares in Q4 2022, an estimated $104K.
  • ALPS Advisors first reported a position in Kronos Bio in Q4 2021 and held it in 4 quarters.
  • ALPS Advisors's Kronos Bio position peaked at $886K in Q4 2021.
  • 97 funds tracked by Wall St. Rank held Kronos Bio as of Q4 2022.

Based on ALPS Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.